Regeneron Pharmaceuticals Faces Securities Class Action
Investors React to Significant Drop in Share Value
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) is currently embroiled in a securities fraud class action lawsuit after experiencing a dramatic decline in its stock price. Following the company’s Q3 2024 earnings report, which disappointed many investors, shares plummeted by $84.59 on October 31, resulting in a massive loss of approximately $9 billion in market capitalization.
The class action was initiated by Hagens Berman, a law firm that is investigating whether Regeneron misled shareholders regarding its EYLEA product, an injection used to manage age-related macular degeneration through the inhibition of vascular endothelial growth factor (VEGF). The investigation urges investors who have incurred substantial losses in Regeneron’s stocks to come forward and report their experiences.
Details of the Class Action
Understanding the Allegations Against Regeneron
The lawsuit primarily centers around Regeneron's statements related to compliance with regulations concerning Medicare reimbursement claims for EYLEA. Allegations suggest that the company made a series of misleading claims. Specifically, they failed to disclose key facts about financial practices linked to EYLEA.
Some of the particular points raised in the complaint include:
- Regeneron purportedly paid credit card fees to distributors with the stipulation that these distributors would not charge higher prices to customers using credit cards.
- These payments significantly subsidized the prices customers faced when purchasing EYLEA.
- This led to a price concession that effectively reduced the selling price of EYLEA.
- Regeneron’s price concessions provided a competitive edge in the market, as retina practices were sensitive to pricing.
- Due to these actions, the reported sales figures for EYLEA were misleadingly inflated.
- Finally, Regeneron failed to classify credit card fees as price concessions, thus misrepresenting the average sales price (ASP) to federal agencies, potentially violating the False Claims Act.
On April 10, 2024, the U.S. Department of Justice announced a lawsuit against Regeneron for alleged violations of the False Claims Act. The DOJ maintains that Regeneron inflated its Medicare reimbursement rates by submitting false reports based on ASP without accounting for price concessions, namely the processing fees for credit cards.
Financial Performance Concerns
Impact of Q3 2024 Earnings on Investor Confidence
Regeneron’s recent earnings report disclosed disappointing net sales figures for its EYLEA and EYLEA HD products. The company noted a mere 3% increase in sales compared to the previous year, attributing this lackluster growth to lower net selling prices and competitive pricing pressures in the anti-VEGF market. This news contributed to a subsequent 9% decline in Regeneron’s share price following the announcement.
Reed Kathrein, a partner at Hagens Berman who is overseeing the investigation, mentioned, "We are probing whether Regeneron potentially misled investors regarding the legality and reality of its revenue reports." This statement highlights the concern regarding the integrity of Regeneron’s financial disclosures.
Next Steps for Affected Investors
How Investors Can Seek Justice
For investors who faced losses from their investments in Regeneron due to the recent developments, there are options available for recourse. If you believe you have been adversely affected, or if you possess information that could assist in the investigation, you are encouraged to report your experiences.
The law firm is actively seeking individuals who have incurred significant losses related to Regeneron stocks. This investigation could reveal important information that may benefit investors in a potential class action suit.
Whistleblower Information
Incentives for Sharing Information
Whistleblowers with non-public knowledge concerning Regeneron’s operations are urged to consider assistance in this investigation. The SEC Whistleblower program offers rewards that can be up to 30% of any successful recovery for original information provided. Those interested can reach out to Reed Kathrein at 844-916-0895 or via email.
Frequently Asked Questions
What triggered the class action against Regeneron?
The class action was triggered by a significant drop in Regeneron's stock price following a disappointing Q3 earnings report, along with allegations of misleading statements regarding compliance with Medicare reimbursement practices.
What are the main allegations in the lawsuit?
The lawsuit alleges that Regeneron misled investors by failing to disclose price concessions related to EYLEA, which inflated reported sales figures and Medicare reimbursement rates.
What is EYLEA and its significance?
EYLEA is a drug developed by Regeneron used to treat age-related macular degeneration, playing a crucial role in the company’s revenue generation.
How can investors participate in the class action?
Investors who have suffered losses and possess relevant information can submit their experiences to the law firm leading the investigation.
What protections do whistleblowers have?
Whistleblowers are protected under the SEC Whistleblower program, which incentivizes reporting by offering financial rewards for information that leads to successful recoveries.
